|
|
(2 intermediate revisions by the same user not shown) |
Line 1: |
Line 1: |
| | | #REDIRECT [[Cholestyramine]] |
| __NOTOC__
| |
| {{Cholestyramine}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Clinical Pharmacology==
| |
| | |
| Cholesterol is probably the sole precursor of [[bile acid]]s. During normal digestion, [[bile acid]]s are secreted into the intestines. A major portion of the [[bile acid]]s is absorbed from the intestinal tract and returned to the liver via the [[enterohepatic circulation]]. Only very small amounts of [[bile acid]]s are found in normal serum.
| |
| | |
| Cholestyramine resin adsorbs and combines with the [[bile acid]]s in the intestine to form an insoluble complex which is excreted in the feces. This results in a partial removal of [[bile acid]]s from the enterohepatic circulation by preventing their absorption. | |
| | |
| The increased fecal loss of [[bile acid]]s due to cholestyramine resin administration leads to an increased oxidation of cholesterol to [[bile acid]]s, a decrease in beta lipoprotein or low-density lipoprotein plasma levels and a decrease in serum cholesterol levels. Although in man, cholestyramine resin produces an increase in hepatic synthesis of cholesterol, plasma cholesterol levels fall.
| |
| | |
| In patients with partial biliary obstruction, the reduction of serum [[bile acid]] levels by cholestyramine resin reduces excess [[bile acid]]s deposited in the dermal tissue with resultant decrease in pruritus.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PREVALITE (CHOLESTYRAMINE) POWDER, FOR SUSPENSION [UPSHER-SMITH LABORATORIES INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd434ef8-8af3-434c-a0a0-9a0b18459ba0 | publisher = | date = | accessdate = 10 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| {{Lipid modifying agents}}
| |
| | |
| [[Category:Hepatology]]
| |
| [[Category:[[bile acid]] sequestrants]]
| |
| [[Category:Cardiovasuclar Drugs]]
| |
| [[Category:Drugs]]
| |